Namaste Technologies (CSE:N; OTCMKTS:NXTTF) provided a detailed look at the unaudited net revenue the company produced during the month of March.

As quoted in the press release:


Namaste Technologies is pleased to announce March 2018 total unaudited net revenue as reported by the Company (including shipping revenues and after discounts and refunds) were C$1,249,670, representing a 74 [percent] revenue increase in March 2018 when compared to March 2017. Namaste’s management team is also pleased to report that the Company’s wholly owned subsidiary, Namaste MD Inc. (“NamasteMD”), has acquired 535 new medical cannabis patients on the NamasteMD platform, representing a 142 [percent] month-over-month increase of patients. NamasteMD allows patients to consult with doctors or nurse practitioners for medical cannabis in a simple and convenient platform from the comfort of their homes. The Company anticipates further acceleration of the growth in the NamasteMD patient network and expects that NamasteMD will be key driver of future revenue.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments; “We are very pleased to be seeing the positive trend of monthly sales increases year-over-year. What is most exciting is our increasing rate of patient acquisition on NamasteMD. With minimal outside marketing we were quietly able to bring on nearly 1,000 patients by the end of the March. We are working on expanding our nurse practitioner team with our partners at O Cannabis we Stand on Guard for Thee Inc. (“O Cannabis”) to accommodate the anticipated growth of patients. We strongly believe that our patients will be a key to our success, along with our strategy to provide our patients with not only the best care but also the largest and best variety of medical cannabis products. We’re proud to be innovating the industry by changing the way that patients access medical cannabis and look forward to continued growth through both the medical cannabis and hardware platforms.”

Click here to read the full press release.

Source: marijuanaindex.com

In the cannabis space this week, retailer Fire & Flower Holdings (TSX:FAF,OTCQX:FFLWF) told investors it will be entering the US market through a novel strategic action.

Meanwhile, two longstanding cannabis partners ended their relationship.

Keep reading... Show less

Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development

Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.

Keep reading... Show less

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.

DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

Keep reading... Show less